



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

January 26, 2022

Gavin Choy  
Acting Chief Financial Officer  
GT Biopharma, Inc.  
9350 Wilshire Blvd  
Suite 203  
Beverly Hills, CA 90212

**Re: GT Biopharma, Inc.**  
**Form 10-K for the period ended December 31, 2020**  
**Filed April 16, 2021**  
**Form 10-Q for the period ended June 30, 2021**  
**Filed August 23, 2021**  
**Form 10-Q for the period ended September 30, 2021**  
**Filed November 10, 2021**  
**File No. 001-40023**

Dear Mr. Choy:

We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences